DRG Epidemiology's coverage of venous thromboembolism comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the incidence of venous thromboembolism for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan, and 10 years for the other countries covered in this report.
DRG Epidemiology's venous thromboembolism forecast will answer the following questions:
- Of all people diagnosed with venous thromboembolism, how many in each country across the world are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of venous thromboembolism over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following venous thromboembolism patient populations:
- Diagnosed VTE Events
- Diagnosed DVT Events
- Diagnosed PE Events
- Diagnosed DVT Events by Drug-Treatment
- Diagnosed PE Events by Drug-Treatment
- Diagnosed Events by Etiology
- Diagnosed Events by Cancer Association
- Diagnosed Events by Recurrence
Note: coverage may vary by country and region.
- Venous Thromboembolism - Epidemiology - Mature Markets Data
- Key Findings
- Event rate of Venous Thromboembolism per 1,000 Among People of All Ages in 2016 and 2036
- Relative Sizes of the Contributing Factors to the Trend in Events of Venous Thromboembolism over the Next 20 Years
- Analysis of Diagnosed Venous Thromboembolism Events Across the Countries Under Study in 2016 by Subtype
- Key Findings
- Epidemiology Data
- Diagnosed Events of VTE
- Drug-Treated VTE Events
- VTE Events by Etiology
- VTE Events by Cancer Association
- VTE Events by Recurrence
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Venous Thromboembolism
- Studies Excluded from the Analysis of Venous Thromboembolism
- Risk/Protective Factors
- Risk/Protective Factors for Venous Thromboembolism
- Literature Review
Author(s): Ema Rodrigues, DSc, MPH
Ema is an epidemiologist with expertise in forecasting incident and prevalent populations within oncology, as well as some cardiovascular indications such as venous thromboembolism. She has significant experience with statistical methods such as multivariate linear regression, conditional logistic regression, principal components analysis, mixed models, hierarchical modeling, and path analysis to account for the complex relationships among various predictors of health outcomes, particularly correlated variables.
She completed her master’s and doctoral degree (MPH, D.Sc.) in Environmental Health at Boston University School of Public Health, where she worked on projects investigating significant predictors of various health outcomes including central nervous system cancer, cognitive function, and birth outcomes.